<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CIMETIDINE <img border="0" src="../images/pr.gif"/></span><br/>(sye-met'i-deen)<br/><span class="topboxtradename">Novocimetine <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Peptol <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Tagamet, </span><span class="topboxtradename">Tagamet HB<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">antisecretory (h<sub>2</sub>-receptor antagonist)</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg, 200 mg, 400 mg, 800 mg tablets; 300 mg/5 mL liquid; 150 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Has high selectivity for histamine H<sub>2</sub>-receptors on parietal cells of the stomach and is an H<sub>2</sub>-receptor antagonist. By inhibition of histamine at the H<sub>2</sub>-receptor sites, it suppresses all phases of daytime and nocturnal basal gastric acid secretion in the stomach. Indirectly
         reduces pepsin secretion; it is not a cholinergic. Has no effect on lower esophageal sphincter pressure, gastric motility
         or emptying.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Blocks the H<sub>2</sub>-receptors on the parietal cells of the stomach, thus decreasing gastric acid secretion, raises the pH of the stomach and,
         thereby, reduces pepsin secretion.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term treatment of active duodenal ulcer and prevention of ulcer recurrence (at reduced dosage) after it is healed. Also
         used for short-term treatment of active benign gastric ulcer, pathologic hypersecretory conditions such as Zollinger-Ellison
         syndrome, and heartburn.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Prophylaxis of stress-induced ulcers, upper GI bleeding, and aspiration pneumonitis; gastroesophageal reflux; chronic urticaria;
         acetaminophen toxicity.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known hypersensitivity to cimetidine or other H<sub>2</sub> receptor antagonists; lactation, pregnancy (category B). 
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Older adults or critically ill patients; impaired renal or hepatic function; organic brain syndrome; gastric ulcers; immunocompromised
         patients, pregnancy (category B).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Duodenal Ulcer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 300 mg q.i.d. <i>or</i> 400 mg b.i.d. <i>or</i> 800 mg h.s. <span class="rdroute">IM/IV</span> 300 mg q68h<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IM/IV</span> 2040 mg/kg/d in 4 divided doses<br/><span class="rdage">Neonate:</span> <span class="rdroute">PO/IM/IV</span> 510 mg/kg/d divided q812h<br/><span class="rdage">Infant:</span> <span class="rdroute">PO/IM/IV</span> 1020 mg/kg/d divided q612h<br/><br/><span class="indicationtitle">Duodenal Ulcer, Maintenance Therapy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400 mg h.s.<br/><br/><span class="indicationtitle">Gastric Ulcer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 300 mg q.i.d. with meals and h.s. <span class="rdroute">IM/IV</span> 300 mg q68h<br/><br/><span class="indicationtitle">Heartburn</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg 24 times/d<br/><br/><span class="indicationtitle">Pathologic Hypersecretory Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 300 mg q.i.d. with meals and h.s., may increase up to 2400 mg/d <span class="rdroute">IM/IV</span> 300 mg q68h, may increase up to 2400 mg/d<br/><br/><span class="impairmenttitle">Adjustment for Renal Impairment</span><br/>Cl<sub>cr</sub> 2040 mL/min: dose q8h; Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give 1 h before or 2 h after an antacid.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>IV administration to neonates, infants and children: Verify correct IV concentration and rate of infusion/injection with physician.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Dilute 300 mg in 18 mL D5W or NS to yield 300 mg/20 mL.  <span class="methodtype">Intermittent:</span> Dilute 300 mg in 50 mL D5W or NS.  <span class="methodtype">Continuous:</span> Further dilute in up to 1000 mL of selected IV solution.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give 300 mg or fraction thereof over at least 5 min.  <span class="methodtype">Intermittent:</span> Give over 1520 min.  <span class="methodtype">Continuous:</span> Give a loading dose of 150 mg at the intermittent infusion rate; then give continuous infusion equally spaced over 24 h.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<b>Amphotericin B,</b>
<b>atropine,</b>
<b>cefamandole,</b>
<b>cefazolin,</b>
<b>chlorpromazine,</b>
<b>pentobarbital,</b>
<b>secobarbital.</b>
<span class="incompattype"> Y-site:</span>
<b> Allopurinol,</b>
<b>amphotericin B cholesteryl complex,</b>
<b>amsacrine,</b>
<b>cefepime,</b>
<b>indomethacin,</b>
<b>warfarin.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Parenteral solutions are stable for 48 h at room temperature when added to commonly used IV solutions for dilution. Follow
            manufacturer's directions.
         </li>
<li>Store all forms of cimetidine at 15°30° C (59°86° F) protected from light unless otherwise
            directed by manufacturer.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fever. <span class="typehead">CV (rare):</span>
<span class="speceff-life">Cardiac arrhythmias and cardiac arrest</span> after rapid IV bolus dose. <span class="typehead">GI:</span> Mild transient diarrhea; severe diarrhea, constipation, abdominal discomfort. <span class="typehead">Hematologic:</span> Increased prothrombin time; neutropenia (rare), thrombocytopenia (rare), <span class="speceff-life">aplastic anemia</span>. <span class="typehead">Metabolic:</span> Slight increase in serum uric acid, BUN, creatinine; transient pain at IM site; hypospermia. <span class="typehead">Musculoskeletal:</span> Exacerbation of joint symptoms in patients with preexisting arthritis. <span class="typehead">CNS:</span> Drowsiness, dizziness, light-headedness, depression, headache, reversible confusional states, paranoid psychosis. <span class="typehead">Skin:</span> Rash, Stevens-Johnson syndrome, reversible alopecia. <span class="typehead">Urogenital:</span> Gynecomastia and breast soreness, galactorrhea, reversible impotence. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Cimetidine may cause false-positive <span class="alt">Hemoccult test for gastric bleeding</span> if test is performed within 15 min of oral cimetidine administration.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Cimetidine decreases the hepatic metabolism of <b>warfarin,</b>
<b>phenobarbital,</b>
<b>phenytoin,</b>
<b>diazepam,</b>
<b>propranolol,</b>
<b>lidocaine,</b>
<b>theophylline,</b> thus increasing their activity and toxicity; <span class="classification">antacids</span> may decrease absorption of cimetidine. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 70% of oral dose absorbed from GI tract.  <span class="typehead">Peak:</span> 11.5 h. <span class="typehead">Distribution:</span> Widely distributed; crosses bloodbrain barrier and placenta. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Most of drug excreted in urine in 24 h; excreted in breast milk. <span class="typehead">Half-Life:</span> 2 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Ulcer healing may occur within the first 2 wk of therapy but generally requires at least 4 wk in most patients. Short-term
            (i.e., 8 wk) therapy of active duodenal ulcer does not prevent ulcer recurrence when drug is discontinued.
         </li>
<li>Monitor pulse of patient during first few days of drug regimen. Bradycardia after PO as well as IV administration should be
            reported. Pulse usually returns to normal within 24 h after drug discontinuation.
         </li>
<li>Monitor I&amp;O ratio and pattern: Particularly in the older adult, severely ill, and in patients with impaired renal function.</li>
<li>Report loss of bowel sounds, absence of bowel movement or flatus, vomiting, crampy pain, abdominal distention. Adynamic ileus
            has been reported in patients receiving cimetidine to prevent and treat stress ulcers.
         </li>
<li>Lab tests: Periodic evaluations of blood count and renal and hepatic function are advised during therapy.</li>
<li>Be alert to onset of confusional states, particularly in the older adult or severely ill patient. Symptoms occur within 23
            d after first dose. Report immediately: drug should be withdrawn. Symptoms usually resolve within 34 d after therapy
            is discontinued.
         </li>
<li>Check BP and report an elevation to the physician, if patient complains of severe headache.</li>
<li>Cimetidine impairs absorption of protein-bound vitamin B<sub>12</sub>; therefore patient who takes cimetidine in divided doses to continuously suppress acid gastric secretion is at risk for vitamin
            B<sub>12</sub> deficiency (no risk for patient who takes drug at bedtime to suppress nocturnal acid production).
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Cimetidine must be taken exactly as prescribed. Sudden discontinuation of therapy reportedly has caused perforation of chronic
            peptic ulcer.
         </li>
<li>Seek advice about self-medication with any OTC drug.</li>
<li>Report breast tenderness or enlargement. Mild bilateral gynecomastia and breast soreness may occur after <img src="../images/special/greaterorequal.gif"/>1
            mo of therapy. It may disappear spontaneously or remain throughout therapy.
         </li>
<li>Report recurrence of gastric pain or bleeding (black, tarry stools or "coffee ground" vomitus) immediately, and notify
            physician if diarrhea continues more than 1 d.
         </li>
<li>Avoid driving and other potentially hazardous activities until reaction to drug is known.</li>
<li>Duodenal or gastric ulcer is a chronic, recurrent condition that requires long-term maintenance drug therapy.</li>
<li>Maintenance therapy at reduced dosage after healing of active duodenal ulcer appears to limit recurrence, particularly if
            patient undertakes other antiulcer therapeutic measures: no smoking, life-style that promotes reduced stress.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>